Mangalam Drugs & Organics has reported results for fourth quarter and year ended March 31, 2012.
The company has posted net loss of Rs 1.92 crore for the quarter ended March 31, 2012, against net profit of Rs 0.55 crore for the corresponding period last fiscal. However, total income increased by 45.88% at Rs 40.57 crore during the quarter under review from Rs 27.81 crore in the year-ago period.
For the full year ended March 31, 2012, the company has posted a fall of 69.71% in its net profit at Rs 0.63 crore for the year ended March 31, 2012 as compared to Rs 2.08 crore in the previous year. However, total income has increased by 20.21% at Rs 153.78 crore for year under review as compared to Rs 127.93 crore for the period ended March 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: